DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call

Friday, July 30, 2010 Corporate News
Email Print This Page Comment
Font : A-A+

CUPERTINO, Calif., July 29 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter

2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at 4:30 pm Eastern Time (
1:30 pm Pacific Time
).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation.  Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook